The placebo effect for gastroenterology: Tool or torment

被引:20
作者
Bernstein, Charles N.
机构
[1] Univ Manitoba, Inflammatory Bowel Dis Clin & Res Ctr, Gastroenterol Sect, Winnipeg, MB R3E 3P4, Canada
[2] Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 3P4, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1016/j.cgh.2006.09.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Placebo generally has a negative connotation both in clinical practice and in clinical trials. In this report the nature of placebo is explored in general and in relation to gastrointestinal diseases. The goodness of placebo is highlighted. PubMed was searched for articles and commentaries on placebo and for systematic reviews on placebo. Selected placebo-controlled trials in gastroenterology were reviewed. There are S key components impacting the placebo response: patient characteristics, practitioner characteristics, practitioner-patient interaction, the nature of the illness being treated, and the treatment being applied and the setting in which it is applied. There are also a number of factors that constitute the placebo response and likely an apply to some extent. These include the natural history of the condition, a regression to the mean (accounting for fluctuation in measurements over time), other time effects (ie, patient learning to cope, practitioner gaining expertise), unidentified parallel interventions (ie, change in habits or exogenous stress), the placebo effect of the administered agent being compared with placebo, and the physiologic effects of the placebo. In summary, there are positive aspects to placebo. Clinicians treating patients with gastrointestinal diseases can harness aspects of the placebo response to improve patient outcomes. Clinical trial planners can harness aspects of the placebo response to design disease-specific trials that can minimize the placebo response.
引用
收藏
页码:1302 / 1308
页数:7
相关论文
共 56 条
[1]
BEHAVIORALLY CONDITIONED IMMUNOSUPPRESSION AND MURINE SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ADER, R ;
COHEN, N .
SCIENCE, 1982, 215 (4539) :1534-1536
[2]
[Anonymous], 1984, NEW ENGL J MED, V310, P737
[3]
[Anonymous], 1996, Guide to Clinical Preventive Services: Report of the U. S. Preventive Services Task Force
[4]
BALINT M, 1955, LANCET, V1, P683
[5]
Benson H, 1996, ANNU REV MED, V47, P193
[7]
BLACKWELL B, 1972, LANCET, V1, P1279
[8]
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia [J].
Blum, AL ;
Talley, NJ ;
O'Moráin, C ;
van Zanten, SV ;
Labenz, J ;
Stolte, M ;
Louw, JA ;
Stubberöd, A ;
Theodórs, A ;
Sundin, M ;
Bolling-Sternevald, E ;
Junghard, O .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (26) :1875-1881
[9]
ANALGESIC EFFECTS OF BRANDING IN TREATMENT OF HEADACHES [J].
BRANTHWAITE, A ;
COOPER, P .
BRITISH MEDICAL JOURNAL, 1981, 282 (6276) :1576-1578
[10]
THE LIE THAT HEALS - THE ETHICS OF GIVING PLACEBOS [J].
BRODY, H .
ANNALS OF INTERNAL MEDICINE, 1982, 97 (01) :112-118